Share this Page:
Using gene profiling, a recent study published in Cancer Discovery has identified four distinct molecular subgroups associated with response to treatment with sunitinib or pazopanib and survival.
The findings demonstrate the effects of the presence of immune cells and angiogenesis on the effectiveness of sunitinib and pazopanib against the cancer, and are important for individualised decision-making.
